Atossa Therapeutics Announces Second COVID-19 Therapeutic Development Program, AT-301 Nasal Spray: Summit Biosciences Retained to Develop and Supply AT-301 Nasal Spray for Clinical Study

In April we launched our AT-H201 COVID-19 HOPE program for the most severely ill COVID-19 patients, commented Steven Quay, M.D., Ph.D., President and CEO of Atossa.